The potential role of long-acting injectable cabotegravir–rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis

BACKGROUND: The use of a combination of the integrase inhibitor, cabotegravir, and the non-nucleoside reverse transcriptase inhibitor, rilpivirine, in a long-acting injectable form is being considered as an antiretroviral treatment option for people with HIV in sub-Saharan Africa. We aimed to model...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Lancet Glob Health
Autors principals: Phillips, Andrew N, Bansi-Matharu, Loveleen, Cambiano, Valentina, Ehrenkranz, Peter, Serenata, Celicia, Venter, Francois, Pett, Sarah, Flexner, Charles, Jahn, Andreas, Revill, Paul, Garnett, Geoff P
Format: Artigo
Idioma:Inglês
Publicat: Elsevier Ltd 2021
Matèries:
Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8050198/
https://ncbi.nlm.nih.gov/pubmed/33770513
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2214-109X(21)00025-5
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars